Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Immuron Limited ( (AU:IMC) ) is now available.
Immuron Limited has announced the issuance of 1,142,909 ordinary fully paid securities, which are set to be quoted on the Australian Securities Exchange (ASX) as of December 15, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase liquidity, reflecting its ongoing efforts to strengthen its financial position and operational capabilities.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapy products for the treatment of gut-mediated diseases.
YTD Price Performance: -50.63%
Average Trading Volume: 1,056,012
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$12.68M
Learn more about IMC stock on TipRanks’ Stock Analysis page.